#Cancer Research #URMC #Indivumed

Indivumed and URMC: A New Era in Cancer Research

Indivumed, a leader in precision oncology, recently announced a groundbreaking collaboration with the esteemed Wilmot Cancer Institute at the University of Rochester Medical Center (URMC). This partnership seeks to transform the landscape of cancer therapeutics by focusing on patient-centric research methods, primarily geared towards the development of novel therapies for patients in urgent need.

Enhancing Cancer Research Through Collaboration

This partnership utilizes Indivumed’s innovative platform, which revolves around the meticulous collection of high-quality surgical tissue samples and comprehensive clinical data. By leveraging these resources, the collaboration aims to expedite the identification and development of novel cancer therapies. URMC’s role in this endeavor includes ensuring the collection and processing of biosamples that comply with Indivumed’s rigorous standard operating procedures (SOPs), with a pivotal goal of minimizing ischemia time to under ten minutes. This is crucial for maintaining sample integrity, which in turn supports robust scientific outcomes.

The collaboration's initial focus is on advanced stages of critical solid tumors, such as colorectal, pancreatic, lung, and breast cancers, all of which pose significant medical challenges. The partnership not only aims to advance the understanding and treatment of these specific cancer types but also opens opportunities for exploring other forms of cancer in the future.

Creating Patient-Derived Tumor Models

A fundamental aspect of this compelling collaboration is the development of well-characterized, patient-derived tumor models (PDTMs). These models will encompass various cell cultures, including classical cell cultures, spheroids, and organoids. By utilizing these advanced models, researchers can refine the process of identifying and validating therapeutic targets, ultimately advancing drug development efforts. Hartmut